• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACL
Click for more information
0.00% $3.77

AUSTRALIAN CLINICAL LABS LIMITED - News & Media

Market Cap $760.9M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Australian Clinical Labs Limited is a private provider of pathology services. Its... Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.More

No News & Media currently available.

(20min delay)
Last
$3.77 		Change
0.000(0.00%) 		Mkt cap ! $760.9M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 698 $4.10
 

Sellers (Offers)

Price($) Vol. No.
$3.59 26 2
View Market Depth
Last trade - 09.50am 02/10/2024 (20 minute delay) ?
Last
$3.78 		  Change
0.000 ( 0.85 %)
Open High Low Volume
$3.83 $3.84 $3.78 17141
Last updated 10.10am 02/10/2024 ?
ACL (ASX) Chart

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Firebird achieves preliminary approvals for its Jinshi plant design Firebird Metals Ltd has reached a significant stage in development of its battery-grade manganese sulphate plant in China
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.